Jan 15 (Reuters) - Keros Therapeutics Inc KROS.O:
KEROS THERAPEUTICS ANNOUNCES ADDITIONAL UPDATE ON THE PHASE 2 TROPOS TRIAL
HALTS ALL DOSING IN TROPOS TRIAL DUE TO SAFETY REVIEW
EXPECTS TO PRESENT TOPLINE DATA IN Q2 2025
TROPOS TRIAL TERMINATED EARLY, PATIENTS TO BE MONITORED
Source text: ID:nGNX4tY1PN
Further company coverage: KROS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.